The objective of this retrospective study is to assess the effectiveness and safety of two beta-emitting prostate-specific membrane antigen (PSMA) radioligands, [177Lu]Lu and [161Tb]Tb, in heavily treated patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 148 cycles of beta-emitting PSMA radioligand therapy were given to 53 patients at a specialized cancer care center in Amman, Jordan. This treatment was offered following the exhaustion of all prior treatment modalities. Approximately half of the cases (n = 26) demonstrated an initial partial response to PSMA radioligand therapy. Moreover, roughly one-fourth of the patients (n = 13) exhibited a sustained satisfactory biochemical response, which qualified them to receive a total of six PSMA radioligand therapy cycles and maintain continued follow-up for additional treatment cycles. This was reflected by an adequate prostate-specific antigen (PSA) decline and a concomitant partial response evident on [68Ga]Ga-PSMA positron emission tomography/computed tomography imaging. A minority of patients (n= 18; 34%) experienced side effects. Generally, these were low-grade and self-limiting toxicities. This study endorses previous research evidence about PSMA radioligand therapy’s safety and efficacy. It also provides the first clinical insight from patients of Arab ethnicity. This should facilitate and promote further evidence, both regionally and internationally.
本回顾性研究旨在评估两种β发射型前列腺特异性膜抗原（PSMA）放射性配体[¹⁷⁷Lu]Lu和[¹⁶¹Tb]Tb，在经多线治疗的转移性去势抵抗性前列腺癌（mCRPC）患者中的有效性与安全性。约旦安曼某专业癌症治疗中心对53例患者进行了共计148个周期的β发射型PSMA放射性配体治疗，所有患者均在接受现有全部治疗方案后接受该疗法。约半数病例（26例）对PSMA放射性配体治疗呈现初始部分缓解。此外，约四分之一患者（13例）表现出持续良好的生化反应，这些患者得以完成总计六个周期的PSMA放射性配体治疗，并继续接受后续治疗周期的随访监测，其疗效体现为前列腺特异性抗原（PSA）水平显著下降，同时[⁶⁸Ga]Ga-PSMA正电子发射断层扫描/计算机断层扫描影像显示部分缓解征象。少数患者（18例，占34%）出现不良反应，总体表现为低级别且具有自限性的毒性反应。本研究验证了既往关于PSMA放射性配体治疗安全性与有效性的证据，并首次提供了阿拉伯族裔患者的临床观察数据，这将为区域及国际范围内进一步积累临床证据提供支持。
肿瘤(癌症)患者之家